Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29024081 | 0.84 | CA2 (0.54) | TTRCA1CA2TP53TSHR | |
| SCHEMBL7551950 | 0.84 | TTR (0.53) | TTRTRPA1 | |
| SCHEMBL9344917 | 0.82 | TSHR (0.52) | TTRCA1CA2TP53TSHR | |
| SCHEMBL2871041 | 0.80 | TTR (0.72) | TTRTRPA1 | |
| SCHEMBL17521526 | 0.79 | LPAR1 (0.51) | TP53TSHRALDH1A1MAPK1HTT | |
| SCHEMBL1682169 | 0.79 | HTT (0.73) | TTRCA1CA2TSHRALDH1A1 | |
| SCHEMBL12806565 | 0.79 | HSD11B1 (0.40) | F2NPC1RAB9A | |
| SCHEMBL4525681 | 0.79 | TTR (0.56) | TTRF2TRPA1 | |
| SCHEMBL4340684 | 0.79 | TP53 (0.61) | CA1CA2TP53TSHRALDH1A1 | |
| SCHEMBL3179793 | 0.79 | LMNA (0.54) | TTRCA1CA2TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| EP-2482823-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI (FR) | 2012-08-08 | — | — | EP | disclosed |
| US-7932283-B2 | Fungicide N-cyclopropyl-sulfonylamide derivatives | BAYER CROPSCIENCE AG (DE) | 2011-04-26 | — | — | US | disclosed |
| WO-2011039338-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI-AVENTIS (FR) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011039338-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI-AVENTIS (FR) | 2011-04-07 | — | — | WO | disclosed |
| US-20090137611-A1 | Fungicide N-Cyclopropyl-Sulfonylamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2009-05-28 | — | — | US | disclosed |
| US-20080108580-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-08 | — | — | US | disclosed |
| US-20080108580-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-08 | — | — | US | disclosed |
| US-20080108580-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-08 | — | — | US | disclosed |
| US-7288528-B2 | Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-30 | — | — | US | disclosed |
| US-7288528-B2 | Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-30 | — | — | US | disclosed |
| US-7288528-B2 | Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-30 | — | — | US | disclosed |
| EP-1572707-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-09-14 | — | — | EP | disclosed |
| US-20050014704-A1 | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004052902-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108580-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SLC5A2, SLC5A1, UGGT1 | TTR 635/4885CA1 4049/4885CA2 1252/4885 |
| US-20050014704-A1 | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SLC5A2, SLC5A1, UGGT1 | TTR 635/4885CA1 4049/4885CA2 1252/4885 |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SLC5A1, SLC5A2, SOST | TTR 3263/4885CA1 2877/4885CA2 335/4885 |
| US-20090137611-A1 | Fungicide N-Cyclopropyl-Sulfonylamide Derivatives | CYP51A1, ERG28, CBR3 | TTR 2985/4885CA1 1871/4885CA2 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.